-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
-
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
-
Media Release
Media Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure
-
Media Release
Media Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure
-
Media Release
Media Statement: FortiHFy Global Clinical Program for Entresto®
-
Media Release
Media Statement: FortiHFy Global Clinical Program for Entresto®
-
Media Release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
-
Media Release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes